January 2026
Depression
What January 2026's 25 new studies found, synthesized from the papers below. All Depression research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Depression, major depressive disorder, MDD, depressive disorder, treatment-resistant depression, then ranked by relevance.
Research in January 2026 indicates that psychedelic and glutamatergic treatments (psilocybin, esketamine, ketamine, DMT) show rapid and sustained antidepressant effects, particularly for treatment-resistant depression, with large effect sizes in meta-analyses and real-world studies. However, evidence is mixed: one RCT found serial ketamine infusions no more effective than placebo for inpatient depression, and most studies are open-label, retrospective, or small, limiting confidence. The main caveats are the lack of long-term safety data, functional unblinding, and the need for larger, controlled trials.
Confidence in the evidence
Low-Moderate- Multiple meta-analyses and systematic reviews (e.g., 18017, 17652, 18931) report large effect sizes for psilocybin and esketamine, but many included studies are open-label or small.
- One large RCT (25219) found ketamine not superior to placebo, introducing inconsistency.
- Most real-world studies (e.g., 18922, 18984, 18995) are retrospective or single-arm, with small samples and no blinding.
- Preclinical and mechanistic studies (e.g., 18944, 18990) support biological plausibility but do not directly confirm clinical efficacy.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| 5-Methoxy-N,N-Dimethyltryptamine: Functional Safety Pharmacology and Video-EEG Assessment of a Short-Acting Serotonergic Psychedelic in Beagle Canines. 2026 | preclinical | 8 | Unclear | 5-MeO-DMT showed no seizure liability in dogs, supporting safety for depression trials. |
| The Use of Psilocybin in the Treatment of Depressive Disorders: A Narrative Review 2026 | narrative review | Supports | Psilocybin shows high therapeutic efficacy compared to conventional treatments for depression. | |
| Multimodal rapid anti-depression: Esketamine combined with dexmedetomidine patient-controlled sleep for treatment-resistant depression - A retrospective study. 2026 | retrospective study | 233 | Supports | Esketamine plus dexmedetomidine patient-controlled sleep was associated with sustained antidepressant response at 1, 3, and 6 months. |
| Single-dose DMT reverses anhedonia and cognitive deficits via restoration of neurogenesis in a stress-induced depression model. 2026 | preclinical | Supports | Single-dose DMT reversed anhedonia and cognitive deficits in a stress-induced depression model via neurogenesis. | |
| Prophylactic esketamine to reduce postpartum depression in primiparae: A multicentre, double-blind, randomised clinical trial. 2026 | RCT | 322 | Supports | Prophylactic esketamine reduced postpartum depression incidence at 3 months (11.59% vs 20.89%). |
| Combining Intranasal Esketamine and Electroconvulsive Therapy in Severe Treatment‑Resistant Depression: A Case Series. 2026 | case series | 4 | Supports | Combined ECT and esketamine was feasible and associated with sustained symptom improvement over 24 weeks. |
| The impact of mindfulness-based stress reduction therapy on individuals with autism spectrum disorder and their caregivers: A systematic review. 2026 | systematic review | Supports | MBSR may improve emotional symptoms including depression in adults with ASD. | |
| Systematic review and meta-analysis of intranasal esketamine for treatment-resistant depression: Evidence from real-world studies. 2026 | systematic review and meta-analysis | Supports | Intranasal esketamine showed large effectiveness (Hedges' g = -1.98) and higher remission odds at 3 months in real-world studies. | |
| Modulating tonic NMDA receptor currents: mechanistic insights into ketamine, esketamine, and dextromethorphan for major depressive disorder and implications for the discovery and development of investigational agents. 2026 | theoretical review | Supports | Ketamine, esketamine, and dextromethorphan likely work by dampening tonic NMDA receptor currents in TRD. | |
| Ketamine in the treatment of bipolar depression 2026 | review | Supports | Ketamine appears an alternative treatment for bipolar depression when first- and second-line treatments fail. | |
| PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION 2026 | narrative review | Supports | Psilocybin therapy demonstrates rapid, robust, and sustained antidepressant effects with high response rates. | |
| Astroglia and depression: A Gliocentric perspective from rodent models to therapeutic insights. 2026 | review | Unclear | Astroglial dysfunction is implicated in depression, and antidepressants may restore astroglial function. | |
| The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence 2026 | review | Supports | Psilocybin produces large reductions in depressive symptoms with durable benefits lasting up to one year. | |
| Psychedelics in psychiatric treatment: a literature review 2026 | literature review | Supports | Psilocybin, LSD, MDMA, and ketamine show therapeutic efficacy in depression and other disorders. | |
| The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression 2026 | systematic review and meta-analysis | Supports | Psilocybin 25 mg in integrated sessions was effective for TRD compared to lower doses. | |
| Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis 2026 | systematic review and meta-analysis | 522 | Supports | Psilocybin-assisted therapy had a large and significant antidepressant effect across 7 RCTs. |
| Serial ketamine infusions not effective as adjunctive care for depression 2026 | RCT | No effect | Serial ketamine infusions were not more effective than midazolam placebo for reducing depressive symptoms. | |
| Long-term effectiveness and side-effects of intranasal esketamine in treatment-resistant depression: real-world, single-arm study of over 100 sessions. 2026 | retrospective single-arm study | 20 | Supports | Long-term intranasal esketamine (mean 129 sessions) significantly reduced depression and anxiety, with 25% remission. |
| Time matters for metas: a systematic review and meta-analysis of ect vs ketamine for depression incorporating time. 2026 | systematic review and meta-analysis | 731 | Mixed | ECT and ketamine efficacy for depression depended on time; baseline depression scores were lower in the ketamine group. |
| Beyond first-line antidepressants: lithium, quetiapine, or esketamine? Integrating meta-analyses and preliminary head-to-head evidence 2026 | systematic review | Supports | Lithium, quetiapine, and esketamine are all effective for TRD, with possible superiority of esketamine over quetiapine. | |
| Symptom trajectories and clinical outcomes of intravenous ketamine in treatment-resistant depression: A real-world study using group-based trajectory modeling. 2026 | retrospective study | 209 | Supports | IV ketamine significantly reduced depression and anxiety, with four distinct symptom trajectory classes. |
| Does psilocybin help with mental health conditions? 2026 | review | Supports | Psilocybin therapy shows potential benefits for depression and substance use disorders. | |
| Efficacy of Oral Ketamine in Patients with Depression and Suicidality: A Retrospective Study. 2026 | retrospective study | 41 | Supports | Oral ketamine significantly reduced depressive symptoms and suicidal ideation after three sessions. |
| Bridging ancient substances and modern psychiatry: the role of classic psychedelics in depression treatment. 2026 | narrative review | Supports | Classic psychedelics yield favorable outcomes in alleviating depression symptoms, likely via neuroplasticity. | |
| Progress, potential and pitfalls of ketamine as a treatment for depression 2026 | review | Supports | IV ketamine and intranasal esketamine have strong evidence for antidepressant effects with adequate safety. |
5-MeO-DMT showed no seizure liability in dogs, supporting safety for depression trials.
preclinical Sample size: 8
Psilocybin shows high therapeutic efficacy compared to conventional treatments for depression.
narrative review
Esketamine plus dexmedetomidine patient-controlled sleep was associated with sustained antidepressant response at 1, 3, and 6 months.
retrospective study Sample size: 233
Single-dose DMT reversed anhedonia and cognitive deficits in a stress-induced depression model via neurogenesis.
preclinical
Prophylactic esketamine reduced postpartum depression incidence at 3 months (11.59% vs 20.89%).
RCT Sample size: 322
Combined ECT and esketamine was feasible and associated with sustained symptom improvement over 24 weeks.
case series Sample size: 4
MBSR may improve emotional symptoms including depression in adults with ASD.
systematic review
Intranasal esketamine showed large effectiveness (Hedges' g = -1.98) and higher remission odds at 3 months in real-world studies.
systematic review and meta-analysis
Ketamine, esketamine, and dextromethorphan likely work by dampening tonic NMDA receptor currents in TRD.
theoretical review
Ketamine appears an alternative treatment for bipolar depression when first- and second-line treatments fail.
review
Psilocybin therapy demonstrates rapid, robust, and sustained antidepressant effects with high response rates.
narrative review
Astroglial dysfunction is implicated in depression, and antidepressants may restore astroglial function.
review
Psilocybin produces large reductions in depressive symptoms with durable benefits lasting up to one year.
review
Psilocybin, LSD, MDMA, and ketamine show therapeutic efficacy in depression and other disorders.
literature review
Psilocybin 25 mg in integrated sessions was effective for TRD compared to lower doses.
systematic review and meta-analysis
Psilocybin-assisted therapy had a large and significant antidepressant effect across 7 RCTs.
systematic review and meta-analysis Sample size: 522
Serial ketamine infusions were not more effective than midazolam placebo for reducing depressive symptoms.
RCT
Long-term intranasal esketamine (mean 129 sessions) significantly reduced depression and anxiety, with 25% remission.
retrospective single-arm study Sample size: 20
ECT and ketamine efficacy for depression depended on time; baseline depression scores were lower in the ketamine group.
systematic review and meta-analysis Sample size: 731
Lithium, quetiapine, and esketamine are all effective for TRD, with possible superiority of esketamine over quetiapine.
systematic review
IV ketamine significantly reduced depression and anxiety, with four distinct symptom trajectory classes.
retrospective study Sample size: 209
Psilocybin therapy shows potential benefits for depression and substance use disorders.
review
Oral ketamine significantly reduced depressive symptoms and suicidal ideation after three sessions.
retrospective study Sample size: 41
Classic psychedelics yield favorable outcomes in alleviating depression symptoms, likely via neuroplasticity.
narrative review
IV ketamine and intranasal esketamine have strong evidence for antidepressant effects with adequate safety.
review
Points of agreement
- Psilocybin, esketamine, and ketamine show rapid and robust antidepressant effects in multiple reviews and meta-analyses.
- Real-world studies consistently report significant symptom reduction with esketamine and ketamine in treatment-resistant depression.
- Preclinical studies support neuroplasticity and neurogenesis as mechanisms for psychedelic antidepressants.
- Safety profiles are generally favorable, with transient and mild adverse events.
Conflicts
- One large RCT (25219) found serial ketamine infusions no more effective than placebo, contradicting many positive observational studies.
- The meta-analysis comparing ECT and ketamine (18989) found baseline differences that complicate interpretation.
- Some studies report high remission rates (e.g., 25% in 18995), while others show lower rates or non-significance.
Gaps
- Long-term safety and durability beyond 6 months are understudied, especially for psilocybin and DMT.
- Most real-world studies lack blinding and randomization, introducing expectancy bias.
- Optimal dosing protocols and treatment schedules remain unclear for psilocybin, ketamine, and esketamine.
- Comparative effectiveness between psychedelics and conventional treatments is not well established.
- Functional unblinding and placebo effects are not adequately controlled in most trials.